The future of resilience innovation will require all hands on deck. Photo via Getty Images

As Houstonians know more than most, a natural disaster can set a thriving city back millions. And, as it seems, these natural disasters aren't going anywhere. The question innovators, governments, insurance companies, and affected citizens keep asking is "what can be done?"

"Over the past decade we've been in and out of several disasters in the billions of dollars of impact," says Richard Seline, managing partner at ResilientH2O Partners. "But it's not without response."

Governments are deploying billions into fixing infrastructure, and Seline gathered risk mitigation experts for a conversation and startup pitch session as a part of Houston Tech Rodeo to discuss the future of this field. The experts weighed in on how risk mitigation and disaster prevention is going to need to be supported by both local and national governments.

Pamela Williams, executive director at BuildStrong Coalition, says she's been in the industry for decades now and has observed new financial support opportunities coming in at a federal level. These entities are looking for cost effective, risk reducing technologies. Innovators can think of these resources as seed funds — with a very high return on investment.

"Investments pre-disaster to draw down risk will save us … up to $11 for every $1 invested," she says on the panel. "Pre-disaster mitigation is where it's at."

And the solutions can't just come from one office within the national government — it needs to be a collaborative effort, she adds.

"We have got to provide flexibility, consistency — and truly be able to leverage all of these resources together so that we can do these transformational unthought of projects," Williams says.

Local governments are also tasked with increasing focus and funding on disaster prevention — maybe even more so than federal agencies, says Ron Prater, executive director at Big City Offices of Emergency Management.

"All disasters are local," he explains. "Locals have to be ready. ...Feds have money and resources but they aren't going to come in and save the day."

Governmental support is going to be needed to advance risk mitigation technology and innovation, but entrepreneurs might also have to seek aid elsewhere.

"While there are funds available for entrepreneurs and innovators, the fact is it will not always come from the government," Seline says. "There are billions of dollars of insurance, reinsurance, and non-traditional financing beginning to emerge — most of it centered around insuratech."

Williams says companies have a unique role to play in the continued conversation of driving these types of inventions.

"Our private sector partners have the ability to convene people," she says, "and bring perspectives to the table that have never before been there to come up with creative solutions."

Cultivating diverse thought leadership is crucial to the equation, says panel moderator Landi Spearman, generational and change management consultant at Organized Shift, who explains that Houston is an especially strategic place for this innovation to occur, since it's the most diverse big city in the country.

"When we think about resilience and people, we get to leverage our diversity of perspective. You get to bring yourself to the solution and you get to include others," she says.

There are a few types of exciting technologies emerging in resilience innovation — from finding ways to optimize and assist brokers and carriers as well as the equipment, technology, and data that's coming out of the public-private sector. One that interests Prater in particular is the opportunity to collect data.

"AI and machine learning are going to improve how (emergency managers) get situation awareness — how accurate it is and how timely it is," he says. "One of their main goals is to share as much information as possible."

The panel concluded with three startup pitches from NanoTech, a fireproofing and insulation product; IVPAir, a device that kills COVID-19 germs right from the air; and Climaguard, a weatherproofing invention to protect cars.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Houston researchers: Here's what it takes to spot a great new idea

houston voices

Having a “promotion focus” really does create a mental lens through which new ideas are more visible.

Key findings:

  • New ideas can be crucially important to businesses, driving innovation and preventing stagnation.
  • Recognizing those ideas, though, isn’t always easy.
  • Nurturing what is known as “promotion focus” can help managers spot fresh ideas.

Whenever the late surgeon Michael DeBakey opened a human chest, he drew on a lifetime of resources: the conviction that heart surgery could and should be vastly improved, the skill to venture beyond medicine’s known horizons and the vision to recognize new ideas in everyone around him, no matter how little formal training they had.

Appreciating new ideas is the heartbeat of business as well as medicine. But innovation is surprisingly hard to recognize. In a pioneering 2017 article, Rice Business Professor Jing Zhou and her colleagues published their findings on the first-ever study of the traits and environments that allow leaders to recognize new ideas.

Recent decades have produced a surge of research looking at how and when employees generate fresh ideas. But almost nothing has been written on another crucial part of workplace creativity: a leader’s ability to appreciate new thinking when she sees it.

Novelty, after all, is what drives company differentiation and competitiveness. Work that springs from new concepts sparks more investigation than work based on worn, already established thought. Companies invest millions to recruit and pay star creatives.

Yet not every leader can spot a fresh idea, and not every workplace brings out that kind of discernment. In four separate studies, Zhou and her coauthors examined exactly what it takes to see a glittering new idea wherever it appears. Their work sets the stage for an entirely new field of future research.

First, though, the team had to define their key terms. “Novelty recognition” is the ability to spot a new idea when someone else presents it. “Promotion focus,” previous research has shown, is a comfort level with new experiences that evokes feelings of adventure and excitement. “Prevention focus” is the opposite trait: the tendency to associate new ideas with danger, and respond to them with caution.

But does having “promotion focus” as opposed to “prevention focus” color the ability to see novelty? To find out, Zhou’s team came up with an ingenious test, artificially inducing these two perspectives through a series of exercises. First, they told 92 undergraduate participants that they would be asked to perform a set of unrelated tasks. Then the subjects guided a fictional mouse through two pencil and paper maze exercises.

While one exercise showed a piece of cheese awaiting the mouse at the end of the maze (the promise of a reward), the other maze depicted a menacing owl nearby (motivation to flee).

Once the participants had traced their way through the mazes with pencils, they were asked to rate the novelty of 33 pictures — nine drawings of space aliens and 24 unrelated images. The students who were prepped to feel an adventurous promotion focus by seeking a reward were much better at spotting the new or different details among these images than the students who’d been cued to have a prevention focus by fleeing a threat.

The conclusion: a promotion focus really does create a mental lens through which new ideas are more visible.

Zhou’s team followed this study with three additional studies, including one that surveyed 44 human resource managers from a variety of companies. For this study, independent coders rated the mission statements of each firm, assessing their cultures as “innovative” or “not innovative.” The HR managers then evaluated a set of written practices — three that had been in use for years, and three new ones that relied on recent technology. The managers from the innovative companies were much better at rating the new HR practices for novelty and creativity. To recognize novelty, in other words, both interior and external environments make a difference.

The implications of the research are groundbreaking. The first ever done on this subject, it opens up a completely new research field with profound questions. Can promotion focus be created? How much of this trait is genetic, and how much based on natural temperament, culture, environment and life experience? Should promotion focus be cultivated in education? If so, what would be the impact? After all, there are important uses for prevention focus, such as corporate security and compliance. Meanwhile, how can workplaces be organized to bring out the best in both kinds of focus?

Leaders eager to put Zhou’s findings to use right away, meanwhile, might look to the real-world model of Michael DeBakey. Practice viewing new ideas as adventures, seek workplaces that actively push innovation and, above all, cultivate the view that every coworker, high or low, is a potential source of glittering new ideas.

---

This article originally appeared on Rice Business Wisdom.

Jing Zhou is the Mary Gibbs Jones Professor of Management and Psychology in Organizational Behavior at the Jones Graduate School of Business of Rice University. Zhou, J., Wang, X., Song, J., & Wu, J. (2017). "Is it new? Personal and contextual influences on perceptions of novelty and creativity." Journal of Applied Psychology, 102(2): 180-202.

Axiom Space-tested cancer drug advances to clinical trials

mission critical

A cancer-fighting drug tested aboard several Axiom Space missions is moving forward to clinical trials.

Rebecsinib, which targets a cancer cloning and immune evasion gene, ADAR1, has received FDA approval to enter clinical trials under active Investigational New Drug (IND) status, according to a news release. The drug was tested aboard Axiom Mission 2 (Ax-2) and Axiom Mission 3 (Ax-3). It was developed by Aspera Biomedicine, led by Dr. Catriona Jamieson, director of the UC San Diego Sanford Stem Cell Institute (SSCI).

The San Diego-based Aspera team and Houston-based Axiom partnered to allow Rebecsinib to be tested in microgravity. Tumors have been shown to grow more rapidly in microgravity and even mimic how aggressive cancers can develop in patients.

“In terms of tumor growth, we see a doubling in growth of these little mini-tumors in just 10 days,” Jamieson explained in the release.

Rebecsinib took part in the patient-derived tumor organoid testing aboard the International Space Station. Similar testing is planned to continue on Axiom Station, the company's commercial space station that's currently under development.

Additionally, the drug will be tested aboard Ax-4 under its active IND status, which was targeted to launch June 25.

“We anticipate that this monumental mission will inform the expanded development of the first ADAR1 inhibitory cancer stem cell targeting drug for a broad array of cancers," Jamieson added.

According to Axiom, the milestone represents the potential for commercial space collaborations.

“We’re proud to work with Aspera Biomedicines and the UC San Diego Sanford Stem Cell Institute, as together we have achieved a historic milestone, and we’re even more excited for what’s to come,” Tejpaul Bhatia, the new CEO of Axiom Space, said in the release. “This is how we crack the code of the space economy – uniting public and private partners to turn microgravity into a launchpad for breakthroughs.”